Most genomic alterations that were involved in MEGSs were enriched in core pathways (RB, P53, and RTK/RAS/PI(3)K pathways) required for GBM pathogenesis [1, 6, 21], providing an important validation for the MEGSA. The gene discussed is TP53; the disease is glioblastoma.